Fidaxomicin for Initial Episode of <i>Clostridioides difficile</i> Infection Reduces Recurrence in Immunocompromised Hosts—a Large Retrospective Cohort Study

ICHs treated with fidaxomicin had significantly lower recurrence rates and fewer complications compared to vancomycin. Despite assumptions, ICHs had recurrence rates similar to immunocompetent patients, highlighting the role of comorbidities and treatment choices. Our findings support fidaxomicin as a preferred first-line option in select ICHs and underscore the need for individualized management strategies to improve outcomes in this high-risk population.